Physician

Benjamin Schwartz, M.D.

According to 2025 Medicare claims, Benjamin Schwartz, M.D. (NPI: 1194188367) practices medical oncology in the Tucson, AZ market, with the plurality of this provider's patient population coming from Pima, AZ. This provider's primary affiliated billing organization is ARIZONA BLOOD AND CANCER SPECIALISTS, PLLC (NPI: 1093370918; TIN: 834425637) and primary practice location at 85716-1729. Schwartz is affiliated with the ABC Network (ACO ID: A5554), participating under the MSSP model.

Schwartz's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 535 traditional Medicare patients, billed 141,429 HCPCS/CPT codes, and received $2,414,626 in Medicare payments. The top billing code was 99204 (New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more). Part D data shows 1,529 prescription claims across 280 beneficiaries totaling $2,665,014 in drug costs, led by Revlimid (Lenalidomide). Open Payments data shows 102 records totaling $2,392. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider has fewer than 5 years of reported Medicare Part B carrier billing data, so a reliable trend cannot be assigned. Concurrently, Part D prescription costs have risen steadily, from $7,733 to $2,665,014. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$1.2M$2.4M2022 Medicare payment: $59,709 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $1,520,250 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $2,414,626 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
2015N/RN/RN/R
2016N/RN/RN/R
2017N/RN/RN/R
2018N/RN/RN/R
2019N/RN/RN/R
2020N/RN/RN/R
2021N/RN/RN/R
2022772,202$59,709
202352089,493$1,520,250
2024535141,429$2,414,626

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$1.3M$2.7M2016 Drug cost: $7,733 (USD; Tot_Drug_Cst)2017 Drug cost: $45,158 (USD; Tot_Drug_Cst)2018 Drug cost: $31,807 (USD; Tot_Drug_Cst)2019 Drug cost: $38,119 (USD; Tot_Drug_Cst)2020 Drug cost: $326,805 (USD; Tot_Drug_Cst)2021 Drug cost: $1,097,179 (USD; Tot_Drug_Cst)2022 Drug cost: $687,956 (USD; Tot_Drug_Cst)2023 Drug cost: $558,942 (USD; Tot_Drug_Cst)2024 Drug cost: $2,665,014 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015N/RN/RN/R
201621119$7,733
201786779$45,158
201863441$31,807
201962540$38,119
202043125$326,805
202152267$1,097,179
202263188$687,956
2023204841$558,942
20242801,529$2,665,014

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
99204New patient office or other outpatient visit with moderate level of medical decision making, if using time, 45 minutes or more136136$117
96413Administration of chemotherapy into vein, 1 hour or less67246$98
99214Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more155334$94
99213Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more353926$65
96372Injection of drug or substance under skin or into muscle91271$11

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
RevlimidLenalidomide391,092$798,909
LenalidomideLenalidomide18504$301,106
PomalystPomalidomide12336$278,814
Sandostatin Lar DepotOctreotide Acetate,mi-Spheres11308$101,165
EliquisApixaban281,510$30,101

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary in 2024

CategoryDefinitionRecordsTotal Reported AmountTop Related Entity
General PaymentsReported payment or transfer-of-value amount.102$2,392PFIZER INC.
Research PaymentsReported research-related payment or transfer-of-value amount.0$0N/R
Ownership / Investment InterestsReported value of ownership or investment interests.0$0N/R

FAQ

What Medicare data is available for Benjamin Schwartz, M.D.?

Tedicare shows public-source Medicare data for Benjamin Schwartz, M.D. (NPI 1194188367), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Benjamin Schwartz, M.D. have ACO affiliation data?

Benjamin Schwartz, M.D. is shown with ACO affiliation data for ABC Network (MSSP, ACO ID A5554).

What billing organization is linked to Benjamin Schwartz, M.D.?

Benjamin Schwartz, M.D. is linked to ARIZONA BLOOD AND CANCER SPECIALISTS, PLLC (billing NPI 1093370918) in the available physician profile data.

Does Benjamin Schwartz, M.D. have Open Payments data?

Benjamin Schwartz, M.D. has 102 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.